Aptose Biosciences Inc. (NASDAQ:APTO) Sees Significant Drop in Short Interest

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,310,000 shares, a decrease of 37.3% from the December 31st total of 2,090,000 shares. Approximately 2.3% of the company’s shares are short sold. Based on an average daily trading volume, of 6,420,000 shares, the short-interest ratio is presently 0.2 days.

Aptose Biosciences Price Performance

APTO traded up $0.01 during mid-day trading on Friday, hitting $0.18. The stock had a trading volume of 221,664 shares, compared to its average volume of 749,333. The stock’s fifty day simple moving average is $0.21 and its 200-day simple moving average is $0.35. The firm has a market capitalization of $10.81 million, a price-to-earnings ratio of -0.06 and a beta of 0.87. Aptose Biosciences has a 1-year low of $0.13 and a 1-year high of $2.20.

Analyst Ratings Changes

Several equities analysts recently weighed in on APTO shares. StockNews.com started coverage on shares of Aptose Biosciences in a report on Friday, January 24th. They issued a “hold” rating on the stock. HC Wainwright restated a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a report on Friday, January 10th.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.